+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035

  • PDF Icon

    Report

  • 598 Pages
  • December 2024
  • Region: Global
  • Roots Analysis
  • ID: 6044674
Description Jump to:

The global CAR T-cell therapy market is estimated to grow from USD 4.6 billion in the current year to USD 15.2 billion by 2035, at a CAGR of 11.4% during the forecast period, till 2035.

CAR T-CELL THERAPY MARKET: GROWTH AND TRENDS

Cancer research continues to be one of the most active segments, in terms of drug development, within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity, drug developers are actively investigating more targeted anti-cancer therapies. Of these, CAR T-cell therapies have emerged as a promising option. CAR T-cell therapy leverages the body’s own immune system to target and eliminate cancer cells. CAR-T cell therapies have been demonstrated to enable complete disease remission, omitting the need for additional treatment; several studies have proven the efficacy of these therapy candidates. It is worth highlighting that close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in the development of CAR T-cell therapies for the treatment of different oncological, non-oncological and other disorders. 

Along with the technological advancements in molecular research, the surge in demand for personalized cancer treatment and increase in the number of clinical trials and multiple therapy approvals are some other considerable factors, aiding the growth of this market. Furthermore, continuous financial support from investors is expected to propel the steady growth for the development of CAR-T cell therapy in the mid to long-term. 

CAR T-CELL THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the CAR T-cell therapy market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

  • CAR-T cell therapies, with over 1240 preclinical / clinical product candidates, represent one of the most active segments in the pharmaceutical domain.
  • Close to 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens.
  • Extensive efforts are underway to improve CAR constructs across successive generations, involving alterations in the scFv region via using different types of gene delivery vectors.
  • Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.
  • In the last eight years, over 970 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of these therapies.
  • 375+ scientists from renowned universities are presently involved in the clinical development of CAR-T cell therapies; these KOLs are primarily based in the US and China.
  • The rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain.
  • Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ instances.
  • More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field.
  • In order to efficiently promote these therapies and sustain their position in the CAR-T cell therapies market, drug developers are actively exploring diverse promotional strategies.
  • Considering the growing prevalence of cancer, technological developments and ongoing approvals, the market for CAR-T cell therapies is poised to witness a steady growth in the foreseen future.
  • With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 10%, during the next decade.

CAR T-CELL THERAPY MARKET: KEY SEGMENTS

Multiple Myeloma is Likely to Dominate the CAR T-Cell Therapy Market During the Forecast Period

Based on target indication, the market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma and others. It is worth highlighting that the market for CAR-T therapies designed to treat large B-cell lymphoma is projected to grow at an annual growth rate of 14%, during the forecast period.

CD19 Targeting Therapies is Expected to Capture Largest Share in the CAR T-Cell Therapy Market During the Forecast Period

Based on target antigen, the market is segmented into CD19, BCMA, CD20, CD19 / CD22 and others. It is worth highlighting that the segment for CD19 is likely to capture more than 65% of the overall market in the coming years. This can be attributed to the success of CD19 targeting therapies, such as Kymriah® (tisagenlecleucel) and Yescarta® (axicabtagene ciloleucel).

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the CAR T-Cell Therapy Market Profiled in the Report:

  • Autolus
  • Bluebird Bio
  • Bristol Myers Squibb
  • Carsgen Therapeutics
  • Cellectis, Gilead Sciences
  • Innovative Cellular Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Wellington Zhaotai Therapies

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Glycostem Therapeutics
  • Chief Executive Officer, Gracell Biotechnologies
  • Chief Operating Officer, TxCell
  • Vice President, Scientific Affairs, Kite Pharma
  • Vice President, Immuno-Oncology, Celyad
  • Manager of Business Development, Waisman Biomanufacturing Competitive Intelligence Manager, Strategy & Business Development, Theravectys
  • Professor of Medicine and Director, Department of Oncology, Changhai Hospital
  • Assistant Professor of Medicine, University of Colorado

CAR T-CELL THERAPY MARKET: RESEARCH COVERAGE

  • The report features an in-depth analysis of the CAR T-cell therapy market, focusing on key market segments, including target antigens, target indication, key geographical regions, sales forecast of drugs and leading players.
  • The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
  • A comprehensive evaluation of the current market landscape of CAR-T cell therapies, considering various parameters, such as type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, HER2-positive breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). It also provides an assessment of the companies involved in the development of CAR T-cell therapies based on their year of establishment, company size and location of headquarters.
  • Examination of completed, ongoing, and planned clinical studies based on parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An analysis of key insights derived from the study featuring a competitive analysis, emphasizing the prevalent target antigens associated with hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with CAR-T therapies. These investigators are recognized as KOLs due to their active engagement in the research and development of CAR T cell therapies. Additionally, the chapter provides a comparative analysis of the KOLs’ expertise, utilizing a proprietary scoring system alongside assessments from third-party evaluations.
  • In-depth profiles of key players in CAR T-cell therapy market, focusing on company overviews, and a brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. In addition, it also includes details of the strategic / venture capital investments made in these companies.
  • An analysis of partnerships established in this sector, covering R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • A detailed evaluation of the investments made in CAR T cell therapy companies with proprietary therapies and technologies, encompassing seed funding, venture capital, capital raised through IPOs and follow-on offerings, as well as grants and debt financing.
  • Detailed analysis of over 11,900 patents filed or granted related to CAR T-cell therapies based on type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted), patent valuation and patent benchmarking.
  • A case study focused on the production of cell therapy products, emphasizing the challenges and providing a comprehensive list of contract service providers and in-house manufacturers involved in this domain.
  • A comprehensive evaluation of the various factors that underpin the pricing of cell-based therapies. It includes different models and strategies that a pharmaceutical company might consider when determining the price of a CAR-T cell therapy expected to be launched in the near future.
  • An analysis of the primary promotional strategies employed by the developers of approved CAR T cell therapies, including Tisagenlecleucel-T (KYMRIAH®), Axicabtagene ciloleucel (YESCARTA®), Brexucabtagene Autoleucel (TECARTUS™), Lisocabtagene maraleucel (Breyanzi®), Idecabtagene Vicleucel (Abecma™), and Ciltacabtagene Autoleucel (CARVYKTI™), among others.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • How many clinical trials are running for CAR-T therapies?
  • What are the factors that are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of T-cell Immunotherapies
5.2.1. Historical Evolution
5.2.2. Key Considerations for Developing T-cell Immunotherapies
5.2.3. Strategies Employed for the Redirection of T-cells
5.2.4. Manufacturing of Engineered T-cells
5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
5.3.1. Development History
5.3.2. Structure of CAR
5.3.2.1. Ectodomain
5.3.2.2. Transmembrane (TM) Domain
5.3.2.3. Endodomain
5.3.3. Development of CAR-T Cells
5.3.4. Universal CAR-T Cells
5.3.5. Route of Administration
5.3.6. Challenges Associated with CAR-T Cell Therapies
5.3.6.1. Competitive Risks
5.3.6.2. Clinical Risks
5.3.6.3. Regulatory Risks
5.3.6.4. Commercial Risks
5.4. Concluding Remarks

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Market Landscape
6.2.2. Analysis by Stage of Development
6.2.3. Analysis by Type of Therapy
6.2.4. Analysis by Target Antigen
6.2.5. Analysis by Target Indication
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Stage of Development and Therapeutic Area
6.2.8. Analysis by Source of T-cells
6.2.9. Analysis by Stage of Development and Source of T-cells
6.2.10. Analysis by Route of Administration
6.2.11. Analysis by Dosage Regimen
6.2.12. Analysis by Target Patient Population
6.2.13. Most Active Industry Players: Analysis by Number of Therapies
6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies
6.3. CAR-T Cell Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Popular Target Antigens
7.2.1. Popular Targets for Hematological Malignancies
7.2.2. Popular Targets for Solid Tumors
7.3. CAR-T Therapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody Used
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Type of Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis of Enrolled Patient  Population by Trial Registration Year
8.3.3. Analysis by Trial Phase
8.3.4. Analysis of Enrolled Patient Population by Trial Phase
8.3.5. Analysis by Trial Registration Year and Trial Phase
8.3.6. Analysis by Trial Status
8.3.7. Analysis by Patient Gender
8.3.8. Analysis by Therapeutic Area
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.13. Analysis by Geography

9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Geographical Location of KOLs
9.4.4. KOL Activeness versus KOL Strength
9.4.5. Most Prominent KOLs: Analysis by RA score
9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. COMPANY PROFILES
10.1. Chapter Overview
10.2. Autolus
10.3. Bluebird Bio
10.4. Bristol Myers Squibb
10.5. CARsgen Therapeutics
10.6. Cellectis
10.7. Gilead Sciences
10.8. Innovative Cellular Therapeutics
10.9. Noile-Immune Biotech
10.10. Novartis
10.11. Sinobioway Cell Therapy
10.12. Takara Bio
10.13. Wellington Zhaotai Therapies

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. CAR-T Cell Therapies: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Partner
11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Intercontinental and Intracontinental Agreements
11.3.8.2. International and Local Agreements

12. FUNDING AND INVESTMENTS ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. CAR-T Cell Therapies: Funding and Investment Analysis
12.3.1. Analysis by Year of Funding
12.3.2. Analysis of Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Amount Invested and Type of Funding
12.3.5. Analysis by Amount Invested by year and Type of Funding Analysis by Type of Investor
12.3.6. Analysis by Geography
12.3.7. Most Active Players
12.3.8. Leading Investors: Analysis by Number of Funding Instances

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. CAR-T Cell Therapies: Patent Analysis
13.3.1. Analysis by Patent Publication Year
13.3.2. Analysis by Patent Application Year
13.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
13.3.4. Analysis by Patent Jurisdiction
13.3.5. Analysis by CPC Symbols
13.3.6. Analysis by Type of Applicant
13.3.7. Leading Industry Players: Analysis by Number of Patents
13.3.8. Leading Non-Industry Players: Analysis by Number of Patents
13.3.9. Leading Patent Assignees: Analysis by Number of Patents
13.4. Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics
13.5. Patent Valuation
13.6. Leading Patents by Number Of Citations

14. CASE STUDY: CELL THERAPY MANUFACTURING
14.1. Chapter Overview
14.2. Overview of Cell Therapy Manufacturing
14.3. Cell Therapy Manufacturing Models
14.3.1. Centralized Manufacturing Model
14.3.2. Decentralized Manufacturing Model
14.4. Scalability of Cell Therapy Manufacturing Processes
14.4.1. Scale-Up
14.4.2. Scale-Out
14.5. Types of Cell Therapy Manufacturers
14.6. Key Challenges Related to Manufacturing of Cell Therapies
14.7. Key Considerations for Cell Therapy Manufacturing
14.7.1. Characterization
14.7.2. Cost of Goods
14.8. Automation of Cell Therapy Manufacturing Process
14.9. Cell Therapy Manufacturing Supply Chain
14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
14.11. Regulatory Landscape
14.12. Future Perspectives

15. COST PRICE ANALYSIS
15.1. Chapter Overview
15.2. Factors Contributing to the High Price of Cell / Gene Therapies
15.3. Pricing Models for T-cell Immunotherapies
15.3.1. Based on Associated Costs
15.3.2. Based on Availability of Competing Products
15.3.3. Based on Patient Population
15.3.4. Based on Opinions of Industry Experts
15.4. Reimbursement related Considerations for T-cell Immunotherapies
15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL CAR-T CELL THERAPY MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Future Estimates (till 2035)
17.4. Scenario Analysis
17.4.1. Conservative Scenario
17.4.2. Optimistic Scenario
17.5. Key Market Segmentations

18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, Current Year and 2035
18.3.1. CART-T Cell Therapies Market for CD19: Forecasted Estimates (till 2035)
18.3.2. CART-T Cell Therapies Market FOR BCMA: Forecasted Estimates (till 2035)
18.3.3. CART-T Cell Therapies Market FOR CD20: Forecasted Estimates (till 2035)
18.3.4. CART-T Cell Therapies Market for CD19 / CD22: Forecasted Estimates (2025-2035)
18.3.5. CAR-T Cell Therapies Market for Other Target Antigens: Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation

19.  CAR-T CELL THERAPY MARKET, BY TARGET INDICATION
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, Current Year and 2035
19.3.1. CAR-T Cell Therapies Market for Multiple Myeloma: Forecasted Estimates (till 2035)
19.3.2. CAR-T Cell Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (till 2035)
19.3.3. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035)
19.3.4. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (till 2035)
19.3.5. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma and Large B-Cell Lymphoma: Forecasted Estimates (till 2035)
19.3.6. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035)
19.3.7. CAR-T Cell Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035)
19.3.8. CAR-T Cell Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035)
19.3.9. CAR-T Cell Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035)
19.3.10. CAR-T Cell Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035)
19.3.11. CAR-T Cell Therapies Market for Renal Transplantation: Forecasted Estimates (till 2035)
19.3.12. CAR-T Cell Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035)
19.3.13. CAR-T Cell Therapies Market for Ovarian / Endometrial cancer: Forecasted Estimates (till 2035)
19.3.14. CAR-T Cell Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (till 2035)
19.3.15. CAR-T Cell Therapies Market for Follicular Lymphoma: Forecasted Estimates (till 2035)
19.3.16. CAR-T Cell Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035)
19.6. Data Triangulation and Validation

20.  CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, Current Year and 2035
20.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035)
20.3.2. CAR-T Cell Therapy Market for Europe: Forecasted Estimates (till 2035)
20.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Forecasted Estimates (till 2035)
20.3.4. CAR-T Cell Therapy Market for Latin America: Forecasted Estimates (till 2035)
20.3.5. CAR-T Cell Therapy Market for Middle East and North Africa: Forecasted Estimates (till 2035)
20.3.6.  CAR-T Cell Therapy Market for Rest of the World: Forecasted Estimates (till 2035)
20.4.  Data Triangulation and Validation

21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Commercialized CAR-T Cell Therapies: Sales Forecast
21.3.1. Kymriah (Tisagenlecleucel-T) Sales Forecast
21.3.2. Yescarta (axicabtagene ciloleucel) Sales Forecast
21.3.3. Tecartus (Brexucabtagene Autoleucel) Sales Forecast
21.3.4. Abecma (Idecabtagene Vicleucel / bb211211) Sales Forecast
21.3.5. CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) Sales Forecast
21.3.6. BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast
21.3.7. Carteyva (Relmacabtagene autoleucel / JWCAR0219) Sales Forecast
21.3.8. NexCART Sales Forecast
21.3.9. Fucaso (Equecabtagene Autoleucel) Sales Forecast
21.3.10. Inaticabtagene Autoleucel CNCT19 / HY001Sales Forecast
21.3.11. Zevorcabtagene autoleucel (CT053) Sales Forecast
21.4.    Clinical CAR-T Cell Therapies: Sales Forecast
21.4.1. CAR-BCMA T cells Sales Forecast
21.4.2. CAR-T-CD19 Cells Sales Forecast
21.4.3. Descartes-08 Sales Forecast
21.4.4. Zamtocabtagene Autoleucel (MB-CART21019.1) Sales Forecast
21.4.5. CAR-T ddBCMA Sales Forecast
21.4.6. CRG-02121 cells Sales Forecast
21.4.7. CT041 Sales Forecast
21.4.8. ALLO-501A / ALLO-501 Sales Forecast
21.4.9. ALLO-605 Sales Forecast
21.4.10. Descartes-25 Sales Forecast
21.4.11. AUTO1 Sales Forecast
21.4.12. AUTO3 (CD19/2121 CAR-T) Sales Forecast
21.4.13. AUTO4 (CD19/2121 CAR-T) Sales Forecast
21.4.14. CD19-CAR-T Sales Forecast
21.4.15. Humanized CD19-CAR-T Sales Forecast
21.4.16. IM19 CAR-T Sales Forecast
21.4.17. CCT301 CAR-T Sales Forecast
21.4.18. CARCIK-CD19 Sales Forecast
21.4.19. CD123 CAR-T cells Sales Forecast
21.4.20. BCMA CAR-T Sales Forecast
21.4.21. CD19/CD22-CAR-T Sales Forecast
21.4.22. GC012F (Dual CAR-BCMA- 19) Sales Forecast
21.4.23. CD19/CD210-CART Sales Forecast
21.4.24. CD7 CAR-T Sales Forecast
21.4.25. Anti-FLT3 CAR-T / TAA05 Sales Forecast
21.4.26. Anti-ALPP CAR-T Cells Sales Forecast
21.4.27. WU CART 007 Sales Forecast
21.4.28. CTX110 Sales Forecast
21.4.29. TX2100-TR101 Sales Forecast
21.4.30. ALETA-001 Sales Forecast
21.4.31. PBCAR0191 Sales Forecast
21.5. Data Triangulation and Validation

22.  CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS
22.1.  Chapter Overview
22.2.  Key Assumptions and Methodology
22.3.  CAR-T Cell Therapies: Leading Players
22.3.1.  Gilead Sciences Sales Forecast
22.3.2.  Bristol Myers Squibb Sales Forecast
22.3.3.  Novartis Sales Forecast
22.3.4.  Janssen Sales Forecast
22.3.5.  JW Therapeutics Sales Forecast
22.4.  Data Triangulation and Validation

23. PROMOTIONAL ANALYSIS
23.1. Chapter Overview
23.2. Channels Used for Promotional Campaigns
23.3. Summary of Product Website Analysis
23.4. Summary of Patient Support Services and Informative Downloads
23.5. Kymriah: Promotional Analysis
23.5.1. Drug Overview
23.5.2. Product Website Analysis
23.5.2.1. Message for Healthcare Professionals
23.5.2.2. Message for Patients
23.5.2.3. Informative Downloads
23.5.3. Patient Support Services
23.6. Yescarta: Promotional Analysis
23.6.1. Drug Overview
23.6.2. Product Website Analysis
23.6.2.1. Message for Healthcare Professionals
23.6.2.2. Message for Patients
23.6.2.3. Informative Downloads
23.6.3. Patient Support Services
23.7. Tecartus: Promotional Analysis
23.7.1. Drug Overview
23.7.2. Product Website Analysis
23.7.2.1. Message for Healthcare Professionals
23.7.2.2. Message for Patients
23.7.2.3. Informative Downloads
23.7.3. Patient Support Services
23.8. Breyanzi: Promotional Analysis
23.8.1. Drug Overview
23.8.2. Product Website Analysis
23.8.2.1. Message for Healthcare Professionals
23.8.2.2. Message for Patients
23.8.2.3. Informative Downloads
23.8.3. Patient Support Services
23.9. Abecma: Promotional Analysis
23.9.1. Drug Overview
23.9.2. Product Website Analysis
23.9.2.1. Message for Healthcare Professionals
23.9.2.2. Message for Patients
23.9.2.3. Informative Downloads
23.9.3. Patient Support Services
23.10. Carvykti: Promotional Analysis
23.10.1. Drug Overview
23.10.2. Product Website Analysis
23.10.2.1. Message for Healthcare Professionals
23.10.2.2. Message for Patients
23.10.2.3. Informative Downloads
23.10.3. Patient Support Services

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Atara Biotherpeutics
24.2.1. Interview Transcript
24.3. Glycostem Therapeutics
24.3.1. Interview Transcript
24.4. Gracell Biotechnologies
24.4.1. Interview Transcript
24.5. TxCell
24.5.1 Interview Transcript
24.6. Kite Pharma
24.6.1. Interview Transcript
24.7. Celyad
24.7.1. Interview Transcript
24.8. Waisman Biomanufacturing
24.8.1. Interview Transcript
24.9. Theravectys
24.9.1. Interview Transcript
24.10. Changhai Hospital
24.10.1. Interview Transcript
24.11. Changhai Hospital
24.11.2. Interview Transcript

25. CONCLUDING REMARKS26. APPENDIX I: TABULATED DATA27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS28. APPENDIX III: LIST OF FUNDING AND INVESTMENTS
LIST OF FIGURES
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Funding and Investments
Figure 4.4 Executive Summary: Patent Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Strategies Employed for the Redirection of T-Cells
Figure 5.2 T-Cell Manufacturing: General Procedure
Figure 5.3 Development History of CAR-T cells
Figure 5.4 Structure of Chimeric Antigen Receptor
Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 5.6 CAR-T Cell Therapies: Development Process
Figure 5.7 Challenges Associated with CAR-T-Cell Therapies
Figure 6.1 CAR-T Cell Therapies: Distribution by Stage of Development
Figure 6.2 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 6.2 CAR-T Cell Therapies: Distribution by Target Antigen
Figure 6.3 CAR-T Cell Therapies: Distribution by Target Indication
Figure 6.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 6.5 CAR-T Cell Therapies: Distribution by Stage of Development and Therapeutic Area
Figure 6.6 CAR-T Cell Therapies: Distribution by Source of T-cells
Figure 6.7 CAR-T Cell Therapies: Distribution by Stage of Development and Source of T-cells
Figure 6.8 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 6.9 CAR-T Cell Therapies: Distribution by Dosage Regimen
Figure 6.10 CAR-T Cell Therapies: Distribution by Target Patient Population
Figure 6.11 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
Figure 6.12 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 6.13 CAR-T Cell Therapies Developers: Distribution by Year of Establishment
Figure 6.14 CAR-T Cell Therapies Developers: Distribution by Company Size
Figure 6.15 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Region)
Figure 6.16 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Country)
Figure 7.1  CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.3 CAR-Construction: Distribution by Generation of CAR
Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Figure 8.1 Clinical Trial Analysis: Cumulative Year-wise Trend
Figure 8.2 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 8.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 8.8 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 8.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 8.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 8.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 8.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 8.13 Leading Industry Players: Distribution by Number of   Registered Trials
Figure 8.14 Leading Non-Industry Players: Distribution by Number of  Registered Trials
Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 8.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 9.1 KOL Analysis: Distribution by Type of Organization
Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 KOL Analysis: Distribution by Qualification
Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 Most Prominent KOLs: Distribution by RA Score
Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend
Figure 12.2 Funding and Investment Analysis: Distribution by Amount Invested
Figure 12.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 12.5 Year-wise Distribution of Amount Invested by Type of Funding, since 2018
Figure 12.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 12.7 Funding and Investment Analysis: Distribution of Funding Instances by Geography (Country)
Figure 12.8 Most Active Players: Distribution by Funding Instances
Figure 12.9 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, since 2018
Figure 13.3 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year
Figure 13.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, since 2018
Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.8 Leading Industry Players: Distribution by Number of Patents
Figure 13.9 Leading Non-industry Players: Distribution by Number of Patents
Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.13 Patent Analysis: Distribution by Patent Age
Figure 13.14 CAR-T Cell Therapy: Patent Valuation
Figure 14.1 Steps for Manufacturing Cell Therapies
Figure 14.2 Centralized Manufacturing: Process Model
Figure 14.3 Decentralized Manufacturing: Process Model
Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 14.5 Cell Therapy: Challenges and Drivers
Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 16.1 CAR-T Cell Therapies: Market Drivers
Figure 16.2 CAR-T Cell Therapies: Market Restraints
Figure 16.3 CAR-T Cell Therapies: Market Opportunities
Figure 16.4 CAR-T Cell Therapies: Market Challenges
Figure 17.1 Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.2 Global CAR-T Cell Therapy Market, till 2035: Conservative Scenario (USD Million)
Figure 17.3 Global CAR-T Cell Therapy Market, till 2035: Optimistic Scenario (USD Million)
Figure 18.1 CAR-T Cell Therapy Market: Distribution by Target Antigen, Current Year and 2035
Figure 18.2 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035) (USD Billion)
Figure 18.3 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035) (USD Billion)
Figure 18.4 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035) (USD Billion)
Figure 18.5 CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (till 2035) (USD Billion)
Figure 18.6 CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.1 CAR-T Cell Therapy Market: Distribution by Target Indication, Current Year and 2035
Figure 19.2 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.3 CAR-T Cell Therapy Market for CAR-T Cell Therapies Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.4 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.5 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.6 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma and Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.7 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.8 CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.9 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.10 CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.11 CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.12 CAR-T Cell Therapy Market for Renal Transplantation: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.13 CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.14 CAR-T Cell Therapy Market for Ovarian / Endometrial Cancer: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.15 CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.16 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 19.17 CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.1 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions,2024, 2030 and 2035
Figure 20.2 CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.3 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.4 CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.5 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.6 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Billion)
Figure 20.7 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035) (USD Billion)
Figure 21.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, till 2035 (USD Million)
Figure 21.2 CAR-T Cell Therapy Market for Yescarta (axicabtageneciloleucel): Sales Forecast, till 2035 (USD Million)
Figure 21.3 CAR-T Cell Therapy Marketfor Tecartus (BrexucabtageneAutoleucel): Sales Forecast, till 2035 (USD Million)
Figure 21.4 CAR-T Cell Therapy Marketfor Abecma (IdecabtageneVicleucel / bb2121): Sales Forecast, till 2035 (USD Million)
Figure 21.5 CAR-T Cell Therapy Marketfor CARVYKTI (LCAR-B38MCAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel): Sales Forecast, till 2035, (USD Million)
Figure 21.6 CAR-T Cell Therapy Marketfor BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, till 2035 (USD Million)
Figure 21.7 CAR-T Cell Therapy Marketfor Carteyva (Relmacabtageneautoleucel / JWCAR029): Sales Forecast, till 2035, (USD Million)
Figure 21.8 CAR-T Cell Therapy Marketfor NexCART: Sales Forecast,till 2035, (USD Million)
Figure 21.9 CAR-T Cell Therapy Marketfor Fucaso (EquecabtageneAutoleucel): Sales Forecast, till 2035, (USD Million)
Figure 21.10 CAR-T Cell Therapy Marketfor Inaticabtagene AutoleucelCNCT19 / HY001: Sales Forecast, till 2035 (USD Million)
Figure 21.11 CAR-T Cell Therapy Marketfor Zevorcabtagene autoleucel (CT053): Sales Forecast, till 2035 (USD Million)
Figure 21.12 CAR-T Cell Therapy Marketfor CAR-BCMA T cells: Sales Forecast, till 2035 (USD Million)
Figure 21.13 CAR-T Cell Therapy Marketfor CAR-T-CD19 cells: Sales Forecast, till 2035 (USD Million)
Figure 21.14 CAR-T Cell Therapy Marketfor Descartes-08: Sales Forecast, till 2035 (USD Million)
Figure 21.15 CAR-T Cell Therapy Marketfor Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, till 2035 (USD Million)
Figure 21.16 CAR-T Cell Therapy Marketfor CAR-T ddBCMA: Sales Forecast, till 2035 (USD Million)
Figure 21.17 CAR-T Cell Therapy Marketfor CRG-02121 cells: Sales Forecast, till 2035 (USD Million)
Figure 21.18 CAR-T Cell Therapy Marketfor CT041: Sales Forecast, till 2035, (USD Million)
Figure 21.19 CAR-T Cell Therapy Marketfor ALLO-501A / ALLO-501: Sales Forecast, till 2035, (USD Million)
Figure 21.20 CAR-T Cell Therapy Marketfor ALLO-605: Sales Forecast, till 2035 (USD Million)
Figure 21.21 CAR-T Cell Therapy Marketfor Descartes-25: Sales Forecast, till 2035 (USD Million)
Figure 21.22 CAR-T Cell Therapy Marketfor AUTO1: Sales Forecast, till 2035 (USD Million)
Figure 21.23 CAR-T Cell Therapy Marketfor AUTO3 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Figure 21.24 CAR-T Cell Therapy Marketfor AUTO4 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Figure 21.25 CAR-T Cell Therapy Marketfor CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.26 CAR-T Cell Therapy Marketfor Humanized CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.27 CAR-T Cell Therapy Marketfor IM19 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.28 CAR-T Cell Therapy Marketfor CCT301 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.29 CAR-T Cell Therapy Marketfor CARCIK-CD19: Sales Forecast, till 2035 (USD Million)
Figure 21.30 CAR-T Cell Therapy Marketfor CD123 CAR-T cells: Sales Forecast, till 2035 (USD Million)
Figure 21.31 CAR-T Cell Therapy Marketfor BCMA CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.32 CAR-T Cell Therapy Marketfor CD19/CD22-CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.33 CAR-T Cell Therapy Marketfor GC012F (Dual CAR-BCMA-19): Sales Forecast, till 2035 (USD Million)
Figure 21.34 CAR-T Cell Therapy Marketfor CD19/CD20-CART: Sales Forecast, till 2035 (USD Million)
Figure 21.35 CAR-T Cell Therapy Marketfor CD7 CAR-T: Sales Forecast, till 2035 (USD Million)
Figure 21.36 CAR-T Cell Therapy Marketfor Anti-FLT3 CAR-T /TAA05: Sales Forecast, till 2035 (USD Million)
Figure 21.37 CAR-T Cell Therapy Marketfor Anti-ALPP CAR-T Cells: Sales Forecast, till 2035 (USD Million)
Figure 21.38 CAR-T Cell Therapy Marketfor WU CART 007: Sales Forecast, till 2035 (USD Million)
Figure 21.39 CAR-T Cell Therapy Marketfor CTX110: Sales Forecast, till 2035 (USD Million)
Figure 21.40 CAR-T Cell Therapy Marketfor TX200-TR101: Sales Forecast, till 2035 (USD Million)
Figure 21.41 CAR-T Cell Therapy Marketfor ALETA-001: Sales Forecast, till 2035 (USD Million)
Figure 21.42 CAR-T Cell Therapy Marketfor PBCAR0191: Sales Forecast, till 2035 (USD Million)
Figure 22.1. CAR-T Cell Therapies Market: Distribution by Key Players
Figure 22.2. CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, till 2035 (USD Million)
Figure 22.3. CAR-T Cell Therapies Market: Janssen Sales Forecast, till 2035 (USD Million)
Figure 22.4. CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, till 2035 (USD Million)
Figure 22.5. CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, till 2035 (USD Million)
Figure 22.6. CAR-T Cell Therapies Market: Novartis Sales Forecast, till 2035 (USD Million)
Figure 23.1 Channels Used for Promotional Campaigns
Figure 23.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 23.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 23.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 23.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 23.6 Product Website Analysis: Yescarta, Messages for Healthcare Professionals
Figure 23.7 Product Website Analysis: Yescarta, Messages for Patients
Figure 23.8 Product Website Analysis: Yescarta, Kite Konnect
Figure 23.9 Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 23.10 Product Website Analysis: Tecartus, Messages for Healthcare Professionals
Figure 23.11 Product Website Analysis: Tecartus, Messages for Patients
Figure 23.12 Product Website Analysis: Tecartus, Kite Konnect
Figure 23.13 Product Website Analysis: Breyanzi, Messages for Healthcare Professional
Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
Figure 23.20 Product Website Analysis: Carvykti,Messages for Patients
Figure 23.21 Product Website Analysis: Carvykti,MyCARVYKTI
Figure 24.1 Concluding Remarks: Market Landscape
Figure 25.2 Concluding Remarks: Clinical Trial Analysis
Figure 25.3 Concluding Remarks: Funding and Investment Analysis
Figure 25.4 Concluding Remarks: Patent Analysis
Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis

LIST OF TABLES
Table 5.1 Key Characteristics of CAR-T Cells
Table 5.2 Comparison of First and Second-Generation CAR-Ts
Table 6.1 CAR-T Cell Therapies: Approved and Clinical Pipeline
Table 6.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-cell, Dosage Regimen, and Target Patient Population
Table 6.3 CAR-T Cell Therapy: Preclinical Pipeline
Table 6.4 List of CAR-T Cells Developers
Table 10.1 Leading CAR-T Cell Therapy Developers
Table 10.2 Autolus: Company Profile
Table 10.3 bluebird Bio: Company Profile
Table 10.4 Bristol Myers Squibb: Company Profile
Table 10.5 CARsgen Therapeutics: Company Profile
Table 10.6 Cellectis: Company Profile
Table 10.7 Gilead Sciences: Company Profile
Table 10.8 Innovative Cellular Therapeutics: Company Profile
Table 10.9 Noile-Immune Biotech: Company Profile
Table 10.10 Novartis: Company Profile
Table 10.11 Sinobioway Cell Therapy: Company Profile
Table 10.12 Takara Bio: Company Profile
Table 10.13 Wellington Zhaotai Therapies: Company Profile
Table 11.1 CAR T Cell Therapy: List of Partnerships and Collaborations
Table 12.1 CAR T Cell Therapies: Funding and Investments, Since 2018
Table 12.2 CAR T Cell Therapies: Summary of Investments
Table 13.1 Patent Analysis: Prominent CPC Sections
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.1 Assessment Strategies for Different Manufacturing Processes
Table 14.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 14.3 Cell Therapy Manufacturing: Companies with In-house Capabilities and Contract Manufacturers
Table 15.1 Price of Marketed Gene / Cell Therapies
Table 15.2 Price of Marketed Targeted Drugs
Table 15.3 CAR-T Cell Therapy: Expert Opinions on Pricing
Table 15.4 CAR-T Cell Therapy: Reimbursement Landscape
Table 21.1 CAR-T Cell Therapy: List of Forecasted Molecules
Table 25.1 CAR-T Cell Therapy:Distribution by Stage of Development
Table 25.2 CAR-T Cell Therapy: Distribution by Type ofTherapy
Table 25.3 CAR-T Cell Therapy: Distribution by Target Antigen
Table 25.4 CAR-T Cell Therapy: Distribution by Target Indication
Table 25.5 CAR-T Cell Therapy: Distribution by Target Therapeutic Area
Table 25.6 CAR-T Cell Therapy: Distribution by Stage of Development and Therapeutic Area
Table 25.7 CAR-T Cell Therapy: Distribution by Source of T- cells
Table 25.8 CAR-T Cell Therapy: Distribution by Stage of Development and Source of T- cells
Table 25.9 CAR-T Cell Therapy: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapy:   Distribution by Dosage Regimen
Table 25.11 CAR-T Cell Therapy:   Distribution by Target Patient Population
Table 25.12 Most Active Industry Players:   Distribution by Number of CAR-T Cell Therapies
Table 25.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell   Therapies
Table 25.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region wise)
Table 25.17 CAR-T Cell Therapy: Distribution by Location of Headquarters (Country wise)
Table 25.18 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Table 25.19 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Table 25.20 CAR-Construction: Distribution by Generation of CAR
Table 25.21 CAR-Construction: Distribution by Type of scFv Antibody Used
Table 25.22 CAR-Construction: Distribution by Type of Virus Used
Table 25.23 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Table 25.24 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
Table 25.25 Clinical Trial Analysis:   Cumulative Year-wise Trend
Table 25.26 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year
Table 25.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 25.28 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
Table 25.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 25.30 Clinical Trial Analysis: Distribution by Trial Status
Table 25.31 Clinical Trial Analysis: Distribution by Patient Gender
Table 25.32 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 25.33 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 25.34 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 25.35 Clinical Trial Analysis: Distribution by Trial Purpose
Table 25.36 Clinical Trial Analysis: Distribution by Design Allocation
Table 25.37 Leading Industry Players: Distribution by Number of   Registered Trials
Table 25.38 Leading Non-industry Players: Distribution by Number of   Registered Trials
Table 25.39 Clinical Trial Analysis: Distribution of Clinical Trials by Status and Geography
Table 25.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 25.41 KOL Analysis: Distribution by Type of Organization
Table 25.42 KOL Analysis: Distribution by Affiliated Organization
Table 25.43 KOL Analysis: Distribution by Qualification
Table 25.44 CAR T-Cell Therapies: Geographical Distribution of KOLs
Table 25.45 Most Prominent KOLs: Distribution by RA Score
Table 25.46 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.47 Partnerships and Collaborations: Cumulative Year-wise Trend
Table 25.48 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.49 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 25.51 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.52 Partnership and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.53 Most Popular Therapies: Distribution by Number of Partnerships
Table 25.54 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.55 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.56 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 25.57 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 25.58 Funding and Investment: Cumulative Distribution of Instances by Year
Table 25.59 Funding and Investment: Cumulative Distribution of Amount Invested by Year
Table 25.60 Funding and Investment: Distribution of Instances by Type of Funding
Table 25.61 Funding and Investment: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.62 Funding and Investment: Distribution by Amount Invested and Type of Funding Year Wise
Table 25.63 Funding and Investment: Distribution by Geography (Region)
Table 25.64 Funding and Investment: Distribution by Geography (Country)
Table 25.65 Most Active Players: Distribution by Lead Investors
Table 25.66 Most Active Players: Distribution by Number of Funding Instances
Table 25.67 Patent Analysis: Distribution by Type of Patent
Table 25.68 Patent Analysis: Distribution by Patent Publication Year
Table 25.69 Patent Analysis: Distribution by Patent Application Year
Table 25.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 25.71 Patent Analysis: Distribution by Patent Jurisdiction
Table 25.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 25.73 Leading Industry Players: Distribution by Number of Patents
Table 25.74 Leading Non-industry Players: Distribution by Number of Patents
Table 25.75 Leading Individual Assignees: Distribution by Number of Patents
Table 25.76 Patent Benchmarking   Analysis: Distribution of    Patent Characteristics (CPC Codes) by Leading Industry Players
Table 25.77 Patent Benchmarking   Analysis: Distribution of   Leading Industry Players by Patent Characteristics (CPC Codes)
Table 25.78 Patent Analysis: Distribution by Patent Age
Table 25.79 CAR-T Cell Therapy: Patent Valuation
Table 25.80 Global CAR-T Cell Therapy Market, Conservative, Base and Optimistic Scenario, till 2035 (USD Million)
Table 25.81 CAR-T Cell Therapy Market: Distribution by Target Antigen, Current Year and 2035
Table 25.82 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035) (USD Million)
Table 25.83 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035) (USD Million)
Table 25.84 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035) (USD Million)
Table 25.85 CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (till 2035) (USD Million)
Table 25.86 CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (till 2035) (USD Million)
Table 25.87 CAR-T Cell Therapy Market: Distribution by Target Indication, Current Year and 2035 (USD Million)
Table 25.88 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035) (USD Million)
Table 25.89 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.90 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035) (USD Million)
Table 25.91 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.92 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.93 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.94 CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.95 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.96 CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (till 2035) (USD Million)
Table 25.97 CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (till 2035) (USD Million)
Table 25.98 CAR-T Cell Therapy Market for Renal transplantation: Forecasted Estimates (till 2035) (USD Million)
Table 25.99 CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.100 CAR-T Cell Therapy Market for Ovarian and endometrial Cancer: Forecasted Estimates (till 2035) (USD Million)
Table 25.101 CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (till 2035) (USD Million)
Table 25.102 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.103 CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (till 2035) (USD Million)
Table 25.104CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, Current Year and 2035
Table 25.105 CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035) (USD Million)
Table 25.106 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Table 25.107 CAR-T Cell Therapy Market in Asia Pacific: Forecasted Estimates (till 2035) (USD Million)
Table 25.108 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Table 25.109 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Table 25.110 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035) (USD Million)
Table 25.111 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, till 2035 (USD Million)
Table 25.112 CAR-T Cell Therapy Market for Yescarta (axicabtageneciloleucel): Sales Forecast, till 2035 (USD Million)
Table 25.113 CAR-T Cell Therapy Market for Tecartus (BrexucabtageneAutoleucel): Sales Forecast, till 2035 (USD Million)
Table 25.114 CAR-T Cell Therapy Market for Abecma (IdecabtageneVicleucel / bb2121): Sales Forecast, till 2035 (USD Million)
Table 25.115 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38MCAR-T / JNJ-68284528 /Ciltacabtagene Autoleucel): Sales Forecast, till 2035, (USD Million)
Table 25.116 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, till 2035 (USD Million)
Table 25.117 CAR-T Cell Therapy Market for Carteyva (Relmacabtageneautoleucel / JWCAR029): Sales Forecast, till 2035, (USD Million)
Table 25.118 CAR-T Cell Therapy Market for NexCART: Sales Forecast,till 2035, (USD Million)
Table 25.119 CAR-T Cell Therapy Market for Fucaso (EquecabtageneAutoleucel): Sales Forecast, till 2035, (USD Million)
Table 25.120 CAR-T Cell Therapy Market for Inaticabtagene AutoleucelCNCT19 / HY001: Sales Forecast, till 2035 (USD Million)
Table 25.121 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, till 2035 (USD Million)
Table 25.122 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, till 2035 (USD Million)
Table 25.123 CAR-T Cell Therapy Market for CAR-T-CD19 cells: Sales Forecast, till 2035 (USD Million)
Table 25.124 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, till 2035 (USD Million)
Table 25.125 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, till 2035 (USD Million)
Table 25.126 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, till 2035 (USD Million)
Table 25.127 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, till 2035 (USD Million)
Table 25.128 CAR-T Cell Therapy Market for CT041: Sales Forecast, till 2035, (USD Million)
Table 25.129 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, till 2035, (USD Million)
Table 23.130 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast, till 2035 (USD Million)
Table 25.131 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, till 2035 (USD Million)
Table 25.132 CAR-T Cell Therapy Market for AUTO1: Sales Forecast, till 2035 (USD Million)
Table 25.133 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Table 25.134 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, till 2035 (USD Million)
Table 25.135 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.136 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.137 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.138 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.139 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, till 2035 (USD Million)
Table 25.140 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, till 2035 (USD Million)
Table 25.141 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.142 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.143 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, till 2035 (USD Million)
Table 25.144 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, till 2035 (USD Million)
Table 25.145 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, till 2035 (USD Million)
Table 25.146 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T /TAA05: Sales Forecast, till 2035 (USD Million)
Table 25.147 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, till 2035 (USD Million)
Table 25.148 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, till 2035 (USD Million)
Table 25.149 CAR-T Cell Therapy Market for CTX110: Sales Forecast, till 2035 (USD Million)
Table 25.150 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, till 2035 (USD Million)
Table 25.151 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, till 2035 (USD Million)
Table 25.152 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, till 2035 (USD Million)
Table 25.153 CAR-T Cell Therapies Market: Distribution by Key Players
Table 25.154 CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, till 2035 (USD Million)
Table 25.155 CAR-T Cell Therapies Market: Janssen Sales Forecast, till 2035 (USD Million)
Table 25.156 CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, till 2035 (USD Million)
Table 25.157 CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, till 2035 (USD Million)
Table 25.158 CAR-T Cell Therapies Market: Novartis Sales Forecast, till 2035 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Autolus
  • Bluebird Bio
  • Bristol Myers Squibb
  • Carsgen Therapeutics
  • Cellectis, Gilead Sciences
  • Innovative Cellular Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Wellington Zhaotai Therapies

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions - Product Image

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

  • Report
  • 343 Pages
  • Global
From
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 174 Pages
  • Global
From
CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025 - Product Image

CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025

  • Report
  • 332 Pages
  • Global
From
CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Forecast to 2029 - Product Image

CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Forecast to 2029

  • Report
  • 266 Pages
  • Global
From
Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography - Product Image

Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography

  • Report
  • 678 Pages
  • Global
From

About the Car T Therapies Market

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer. Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer. Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.